200 related articles for article (PubMed ID: 28447791)
1. Discovery of a Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor (HSK0935) for the Treatment of Type 2 Diabetes.
Li Y; Shi Z; Chen L; Zheng S; Li S; Xu B; Liu Z; Liu J; Deng C; Ye F
J Med Chem; 2017 May; 60(10):4173-4184. PubMed ID: 28447791
[TBL] [Abstract][Full Text] [Related]
2. TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity.
Yamamoto K; Uchida S; Kitano K; Fukuhara N; Okumura-Kitajima L; Gunji E; Kozakai A; Tomoike H; Kojima N; Asami J; Toyoda H; Arai M; Takahashi T; Takahashi K
Br J Pharmacol; 2011 Sep; 164(1):181-91. PubMed ID: 21410690
[TBL] [Abstract][Full Text] [Related]
3. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level.
Katsuno K; Fujimori Y; Takemura Y; Hiratochi M; Itoh F; Komatsu Y; Fujikura H; Isaji M
J Pharmacol Exp Ther; 2007 Jan; 320(1):323-30. PubMed ID: 17050778
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors.
Mascitti V; Maurer TS; Robinson RP; Bian J; Boustany-Kari CM; Brandt T; Collman BM; Kalgutkar AS; Klenotic MK; Leininger MT; Lowe A; Maguire RJ; Masterson VM; Miao Z; Mukaiyama E; Patel JD; Pettersen JC; Préville C; Samas B; She L; Sobol Z; Steppan CM; Stevens BD; Thuma BA; Tugnait M; Zeng D; Zhu T
J Med Chem; 2011 Apr; 54(8):2952-60. PubMed ID: 21449606
[TBL] [Abstract][Full Text] [Related]
5. N-Indolylglycosides bearing modifications at the glucose C6-position as sodium-dependent glucose co-transporter 2 inhibitors.
Chu KF; Yao CH; Song JS; Chen CT; Yeh TK; Hsieh TC; Huang CY; Wang MH; Wu SH; Chang WE; Chao YS; Lee JC
Bioorg Med Chem; 2016 May; 24(10):2242-50. PubMed ID: 27075813
[TBL] [Abstract][Full Text] [Related]
6. The role of SGLT2 inhibitors in managing type 2 diabetes.
Tat V; Forest CP
JAAPA; 2018 Jun; 31(6):35-40. PubMed ID: 29846314
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel N-β-D-xylosylindole derivatives as sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycemia in diabetes.
Yao CH; Song JS; Chen CT; Yeh TK; Hung MS; Chang CC; Liu YW; Yuan MC; Hsieh CJ; Huang CY; Wang MH; Chiu CH; Hsieh TC; Wu SH; Hsiao WC; Chu KF; Tsai CH; Chao YS; Lee JC
J Med Chem; 2011 Jan; 54(1):166-78. PubMed ID: 21128592
[TBL] [Abstract][Full Text] [Related]
8. SHR3824, a novel selective inhibitor of renal sodium glucose cotransporter 2, exhibits antidiabetic efficacy in rodent models.
Yan PK; Zhang LN; Feng Y; Qu H; Qin L; Zhang LS; Leng Y
Acta Pharmacol Sin; 2014 May; 35(5):613-24. PubMed ID: 24786232
[TBL] [Abstract][Full Text] [Related]
9. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
Meng W; Ellsworth BA; Nirschl AA; McCann PJ; Patel M; Girotra RN; Wu G; Sher PM; Morrison EP; Biller SA; Zahler R; Deshpande PP; Pullockaran A; Hagan DL; Morgan N; Taylor JR; Obermeier MT; Humphreys WG; Khanna A; Discenza L; Robertson JG; Wang A; Han S; Wetterau JR; Janovitz EB; Flint OP; Whaley JM; Washburn WN
J Med Chem; 2008 Mar; 51(5):1145-9. PubMed ID: 18260618
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of thiophene-C-glucosides as sodium-dependent glucose cotransporter 2 inhibitors.
Sakamaki S; Kawanishi E; Koga Y; Yamamoto Y; Kuriyama C; Matsushita Y; Ueta K; Nomura S
Chem Pharm Bull (Tokyo); 2013; 61(10):1037-43. PubMed ID: 24088695
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo.
Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Qun L; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
Naunyn Schmiedebergs Arch Pharmacol; 2012 Apr; 385(4):423-36. PubMed ID: 22139434
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 6-deoxydapagliflozin as a highly potent sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
Zhang L; Wang Y; Xu H; Shi Y; Liu B; Wei Q; Xu W; Tang L; Wang J; Zhao G
Med Chem; 2014 May; 10(3):304-17. PubMed ID: 24059684
[TBL] [Abstract][Full Text] [Related]
13. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic Agents.
Choi CI
Molecules; 2016 Aug; 21(9):. PubMed ID: 27618891
[TBL] [Abstract][Full Text] [Related]
14. Swertisin, a novel SGLT2 inhibitor, with improved glucose homeostasis for effective diabetes therapy.
Bhardwaj G; Vakani M; Srivastava A; Patel D; Pappachan A; Murumkar P; Shah H; Shah R; Gupta S
Arch Biochem Biophys; 2021 Oct; 710():108995. PubMed ID: 34289381
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of C-glucosides with azulene rings as selective SGLT2 inhibitors for the treatment of type 2 diabetes mellitus: discovery of YM543.
Ikegai K; Imamura M; Suzuki T; Nakanishi K; Murakami T; Kurosaki E; Noda A; Kobayashi Y; Yokota M; Koide T; Kosakai K; Ohkura Y; Takeuchi M; Tomiyama H; Ohta M
Bioorg Med Chem; 2013 Jul; 21(13):3934-48. PubMed ID: 23651509
[TBL] [Abstract][Full Text] [Related]
16. SGLT2 inhibitors: molecular design and potential differences in effect.
Isaji M
Kidney Int Suppl; 2011 Mar; (120):S14-9. PubMed ID: 21358697
[TBL] [Abstract][Full Text] [Related]
17. C-Aryl 5a-carba-β-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
Ohtake Y; Sato T; Matsuoka H; Kobayashi T; Nishimoto M; Taka N; Takano K; Yamamoto K; Ohmori M; Higuchi T; Murakata M; Morikawa K; Shimma N; Suzuki M; Hagita H; Ozawa K; Yamaguchi K; Kato M; Ikeda S
Bioorg Med Chem; 2012 Jul; 20(13):4117-27. PubMed ID: 22652255
[TBL] [Abstract][Full Text] [Related]
18. C-aryl glucosides substituted at the 4'-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
Xu B; Feng Y; Cheng H; Song Y; Lv B; Wu Y; Wang C; Li S; Xu M; Du J; Peng K; Dong J; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Roberge JY; Seed B; Chen Y
Bioorg Med Chem Lett; 2011 Aug; 21(15):4465-70. PubMed ID: 21737266
[TBL] [Abstract][Full Text] [Related]
19. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models.
Fujimori Y; Katsuno K; Nakashima I; Ishikawa-Takemura Y; Fujikura H; Isaji M
J Pharmacol Exp Ther; 2008 Oct; 327(1):268-76. PubMed ID: 18583547
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of 6-deoxy O-spiroketal C-arylglucosides as novel renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
Wang Y; Lou Y; Wang J; Li D; Chen H; Zheng T; Xia C; Song X; Dong T; Li J; Li J; Liu H
Eur J Med Chem; 2019 Oct; 180():398-416. PubMed ID: 31325786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
